ELAVL2 gene – Talk Bio

Amgen to Invest Over $600M in New Innovation Centre at California Headquarters

1 week ago talkbio0Tagged amgen, Automation, Biotechnology, California, Capital, Construction worker, digital tools, ELAVL2 gene, Incentives, innovation, innovation centre, Investments, Science, therapeutic development, Thousand Oaks

Amgen; innovation centre; science and innovation hub; Thousand Oaks; California; biotechnology; construction; automation; digital tools; therapeutic development; tax incentives; capital investment

Biogen’s New Global Headquarters: Consolidating Operations in Cambridge

6 months ago talkbio0Tagged Biogen, Cambridge, ELAVL2 gene, headquarters, innovation, Kendall Square, Open

Biogen, Cambridge, Kendall Square, headquarters consolidation, innovation hub, 2028 opening

GE HealthCare and UCSF Collaborate on Innovative Imaging Solutions for Cancer and Neurodegenerative Diseases

8 months ago talkbio0Tagged brain health, Cancer Imaging, ELAVL2 gene, GE HealthCare, innovation, Joint Research Program, Neoplasms, Neurodegenerative Disease Imaging, Precision - temporal, UCSF

GE HealthCare, UCSF, Cancer Imaging, Neurodegenerative Disease Imaging, Precision Oncology, Brain Health, Joint Research Program, Care Innovation Hub

GE HealthCare and UCSF Launch ‘Care Innovation Hub’ to Revolutionize Medical Imaging for Cancer and Neurodegenerative Diseases

8 months ago talkbio0Tagged Automated (qualifier value), brain health, ELAVL2 gene, GE HealthCare, innovation, Magnetic Resonance Imaging, Medical Imaging, Neoplasms, Neurodegenerative Disorders, Precision - temporal, radiopharmaceutical therapies, UCSF

GE HealthCare, UCSF, Care Innovation Hub, medical imaging, cancer, neurodegenerative diseases, precision oncology, brain health, automated imaging techniques, MRI, radiopharmaceutical therapies.